Synthesis of natural molecule could lead to better anti-cancer drugs

January 23, 2008

EVANSTON, Ill. --- In early 2007, Northwestern University chemist Karl Scheidt's interest was piqued when marine chemist Amy Wright reported in the Journal of Natural Products that a new natural compound derived from an uncommon deep-sea sponge was extremely effective at inhibiting cancer cell growth.

As a synthetic chemist fascinated by natural products and their potential in medicine, Scheidt knew what he had to do: Make that molecule.

After six months of intense effort, Scheidt, graduate student Daniel Custar and postdoctoral fellow Thomas Zabawa successfully built the molecular structure reported in the paper. That's when they discovered something strange and unexpected when they compared the spectra, or unique molecular fingerprints, of their structure and that of the natural compound: The spectra did not match, which meant that the structures did not match. Something was wrong.

This story and how the Northwestern team solved the mystery and determined the real structure of neopeltolide, the natural compound derived from the marine sponge, is reported in a paper published in the Jan. 23 issue of the Journal of the American Chemical Society (JACS). Knowing neopeltolide's structure will help researchers learn how the new compound works, which could lead to new, more-effective anti-cancer drugs.

"The reported biological activity of this new natural compound was fantastic -- two to three orders of magnitude more potent for some cancer cells than Taxol®, a common chemotherapy drug," said Scheidt, assistant professor of chemistry in the Weinberg College of Arts and Sciences at Northwestern. (Taxol® also has its origins in nature, having been extracted from the Pacific yew tree.) "Synthetic chemists are inspired by such structures. Because of the potential benefits to human health, these are the compounds you want to go after."

Marine sponges can't move and escape predators, and they don't have claws, teeth or quills, so they have developed a different kind of defense mechanism: chemical protection. The sponge and/or bacteria hosted by the sponge produce poisonous compounds to ward off enemies. This chemical factory makes sponges rich sources of interesting natural products, many with cell-killing abilities.

After discovering the spectrum of their first built molecule did not match the natural compound's spectrum, Scheidt and his team faced two possibilities -- either they had done something wrong while building the molecule or the structure was reported incorrectly.

The researchers double checked their methods, found they were "spot on" and concluded the structure was reported incorrectly. Which meant the right structure still needed to be determined. Custar and Zabawa decided to set up a cot in the lab's computer room to cut down on their commute to the lab and set to work.

Again, using simple starting materials and complex chemical synthesis, the team built a new molecule, just slightly different from the first one. This time they perturbed just two carbon atoms, making them "down" instead of "up," in chemist speak. The researchers compared the spectrum of this new structure with that of the natural compound, and this time the spectra matched perfectly. These results are those published in the JACS article.

To construct the compound, Scheidt, Custar and Zabawa used an efficient, convergent synthesis, a bit akin to how a car is put together on an assembly line -- with major parts, like the engine, built separately and then put together in the final piece. "Our approach brings three equal fragments together to form the whole, which is better than building in a linear sequence," said Scheidt. "We pushed the envelope of what can be done with organic chemistry to do it."

Unbeknownst to the Northwestern researchers, a group led by James S. Panek, an organic chemist at Boston University, was working on the neopeltolide structure at the same time as Scheidt and his team. In their work, Panek's group also discovered the original published structure to be incorrect and determined the correct structure, using steps different from Scheidt's to get there. Panek's results were published a few weeks after the time Scheidt submitted his paper to JACS.

"The synthetic chemists have done an amazing job in such a short time," said Wright, who works at the Harbor Branch Oceanographic Institution. Wright isolated neopeltolide from a sponge she collected near Jamaica in 1993; she and her team reported its biological activity and structure in the 2007 article that inspired Scheidt's work.

"I was impressed with the molecular modeling work that Karl's group did to propose a variety of structures," said Wright. "The beauty is that we can find a compound in nature, and synthetic chemists can then build the structure in the lab. That structure and related compounds can then be tested for drug discovery."

"Nature is the biggest pharmacy around," said Scheidt. "Sixty to seventy percent of pharmaceuticals are inspired by natural products. We learn from nature, but we want to improve on nature, too."

Neopeltolide stops cell division in an unusual place, and this activity is different from that of other commonly known and utilized chemotherapies. "We know there is something different going on with this new molecule, and we want to start figuring out if this behavior is the beginning of a new way to treat cancer," said Scheidt.

In addition to the original structure, Scheidt and his team currently have six or seven other synthetic compounds to test. The researchers want to see if they can make a smaller, simpler molecule that is just as effective against cancer cells but also more selective, leaving healthy cells alone. A few small chemical tweaks may be all that is needed.

With the new compound's correct structure in hand, the real journey can begin, says Scheidt. He plans to work with Wright and Professor Craig Crews, a molecular biologist at Yale University, to screen the tweaked molecules against different cancer cell lines and to discover how they work so new pathways for treating cancer can be identified.
-end-


Northwestern University

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.